Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29616
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorWATANABE, I. K. M.-
dc.contributor.authorJARA, Z. P.-
dc.contributor.authorVOLPINI, R. A.-
dc.contributor.authorFRANCO, M. D. C.-
dc.contributor.authorJUNG, F. F.-
dc.contributor.authorCASARINI, D. E.-
dc.date.accessioned2018-11-21T17:06:46Z-
dc.date.available2018-11-21T17:06:46Z-
dc.date.issued2018-
dc.identifier.citationJOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE, v.9, n.5, p.530-535, 2018-
dc.identifier.issn2040-1744-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29616-
dc.description.abstractPrevious studies have shown that the renin-angiotensin system (RAS) is affected by adverse maternal nutrition during pregnancy. The aim of this study was to investigate the effects of a maternal low-protein diet on proinflammatory cytokines, reactive oxygen species and RAS components in kidney samples isolated from adult male offspring. We hypothesized that post-weaning losartan treatment would have beneficial effects on RAS activity and inflammatory and oxidative stress markers in these animals. Pregnant Sprague-Dawley rats were fed with a control (20% casein) or low-protein diet (LP) (6% casein) throughout gestation. After weaning, the LP pups were randomly assigned to LP and LP-losartan groups (AT(1) receptor blockade: 10 mg/kg/day until 20 weeks of age). At 20 weeks of age, blood pressure levels were higher and renal RAS was activated in the LP group. We also observed several adverse effects in the kidneys of the LP group, including a higher number of CD3, CD68 and proliferating cell nuclear antigen-positive cells and higher levels of collagen and reactive oxygen species in the kidney. Further, our results revealed that post-weaning losartan treatment completely abolished immune cell infiltration and intrarenal RAS activation in the kidneys of LP rats. The prevention of augmentation of angiotensin (Ang II) concentration abolished inflammatory and fibrotic events, indicating that Ang II via the AT(1) receptor is essential for pathological initiation. Our results suggest that the prenatal programming of hypertension is dependent on the up-regulation of local RAS and presence of immune cells in the kidney.-
dc.description.sponsorshipFAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil) [2009/14006-5]-
dc.language.isoeng-
dc.publisherCAMBRIDGE UNIV PRESS-
dc.relation.ispartofJournal of Developmental Origins of Health and Disease-
dc.rightsrestrictedAccess-
dc.subjectinflammation-
dc.subjectlosartan-
dc.subjectlow-protein diet-
dc.subjectprenatal programming-
dc.subjectrenin-angiotensin system-
dc.subject.otheroxidative stress-
dc.subject.otheradhesion molecule-1-
dc.subject.otherblood-pressure-
dc.subject.othert-cell-
dc.subject.otherhypertension-
dc.subject.otherkidney-
dc.subject.otherrats-
dc.titleUp-regulation of renal renin-angiotensin system and inflammatory mechanisms in the prenatal programming by low-protein diet: beneficial effect of the post-weaning losartan treatment-
dc.typearticle-
dc.rights.holderCopyright CAMBRIDGE UNIV PRESS-
dc.identifier.doi10.1017/S2040174418000296-
dc.identifier.pmid29729681
dc.subject.wosPublic, Environmental & Occupational Health-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalWATANABE, I. K. M.:Univ Fed Sao Paulo, Nephrol Div, Dept Med, Sao Paulo, Brazil-
hcfmusp.author.externalJARA, Z. P.:Univ Fed Sao Paulo, Nephrol Div, Dept Med, Sao Paulo, Brazil-
hcfmusp.author.externalFRANCO, M. D. C.:Univ Fed Sao Paulo, Nephrol Div, Dept Med, Sao Paulo, Brazil-
hcfmusp.author.externalJUNG, F. F.:Georgetown Univ, Dept Pediat, Washington, DC 20057 USA-
hcfmusp.author.externalCASARINI, D. E.:Univ Fed Sao Paulo, Nephrol Div, Dept Med, Sao Paulo, Brazil-
hcfmusp.description.beginpage530-
hcfmusp.description.endpage535-
hcfmusp.description.issue5-
hcfmusp.description.volume9-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000445853200008-
hcfmusp.origem.id2-s2.0-85046435184-
hcfmusp.publisher.cityCAMBRIDGE-
hcfmusp.publisher.countryENGLAND-
hcfmusp.relation.referenceAraujo M, 2014, ANTIOXID REDOX SIGN, V20, P74, DOI 10.1089/ars.2013.5259-
hcfmusp.relation.referenceCarey RM, 2015, ADV CHRONIC KIDNEY D, V22, P204, DOI 10.1053/j.ackd.2014.11.004-
hcfmusp.relation.referenceCat AND, 2013, ANTIOXID REDOX SIGN, V19, P1110, DOI 10.1089/ars.2012.4641-
hcfmusp.relation.referenceChavatte-Palmer P, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060586-
hcfmusp.relation.referenceCrowley SD, 2008, AM J PHYSIOL-RENAL, V295, pF515, DOI 10.1152/ajprenal.00527.2007-
hcfmusp.relation.referenceEriksson JG, 2016, ANN MED, V48, P456, DOI 10.1080/07853890.2016.1193786-
hcfmusp.relation.referenceFranco MDP, 2003, CARDIOVASC RES, V59, P767, DOI 10.1016/S0008-6363(03)00461-9-
hcfmusp.relation.referenceGrigore D, 2007, AM J PHYSIOL-REG I, V293, pR804, DOI 10.1152/ajpregu.00725.2006-
hcfmusp.relation.referenceGuzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657-
hcfmusp.relation.referenceHoch NE, 2009, AM J PHYSIOL-REG I, V296, pR208, DOI 10.1152/ajpregu.90521.2008-
hcfmusp.relation.referenceIngert C, 2002, AM J PHYSIOL-RENAL, V283, pF1003, DOI 10.1152/ajprenal.00322.2001-
hcfmusp.relation.referenceJurewicz M, 2007, J AM SOC NEPHROL, V18, P1093, DOI 10.1681/ASN.2006070707-
hcfmusp.relation.referenceKett MM, 2011, AM J PHYSIOL-REG I, V300, pR791, DOI 10.1152/ajpregu.00791.2010-
hcfmusp.relation.referenceKintscher U, 2001, HYPERTENSION, V37, P587, DOI 10.1161/01.HYP.37.2.587-
hcfmusp.relation.referenceLea Amanda J., 2017, Evolution Medicine and Public Health, P162, DOI 10.1093/emph/eox019-
hcfmusp.relation.referenceMcMaster WG, 2015, CIRC RES, V116, P1022, DOI 10.1161/CIRCRESAHA.116.303697-
hcfmusp.relation.referencePaixao AD, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.111823-
hcfmusp.relation.referencePastore L, 1999, CIRCULATION, V100, P1646, DOI 10.1161/01.CIR.100.15.1646-
hcfmusp.relation.referencePueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645-
hcfmusp.relation.referenceRuiz-Ortega M, 2002, KIDNEY INT, V62, pS12, DOI 10.1046/j.1523-1755.62.s82.4.x-
hcfmusp.relation.referenceSherman RC, 2000, CLIN SCI, V98, P269, DOI 10.1042/CS19990275-
hcfmusp.relation.referenceStewart T, 2005, KIDNEY INT, V68, P2180, DOI 10.1111/j.1523-1755.2005.00674.x-
hcfmusp.relation.referenceVehaskari VM, 2001, KIDNEY INT, V59, P238, DOI 10.1046/j.1523-1755.2001.00484.x-
hcfmusp.relation.referenceWoods LL, 2004, KIDNEY INT, V65, P1339, DOI 10.1111/j.1523-1755.2004.00511.x-
dc.description.indexMEDLINE-
dc.identifier.eissn2040-1752-
hcfmusp.citation.scopus8-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - LIM/12
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais


Files in This Item:
File Description SizeFormat 
art_WATANABE_Upregulation_of_renal_reninangiotensin_system_and_inflammatory_mechanisms_2018.PDF
  Restricted Access
publishedVersion (English)731.03 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.